J.R.S. Oryx Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
- Paid Up Capital ₹ 2.64 M
- Company Age 31 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.85 Cr
- Satisfied Charges ₹ 1.77 Cr
- Revenue Growth -20.75%
- Profit Growth 3.22%
- Ebitda 74.83%
- Net Worth 68.97%
- Total Assets 18.26%
About J.R.S. Oryx Pharmaceuticals
J.R.S. Oryx Pharmaceuticals Pvt Ltd (JOPPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 16 April 1993 and has a history of 31 years and ten months. Its registered office is in Karnal, Haryana, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 2.64 M.
The company currently has active open charges totaling ₹2.85 Cr. The company has closed loans amounting to ₹1.77 Cr, as per Ministry of Corporate Affairs (MCA) records.
Surinder Pal and Rattan Sharma serve as directors at the Company.
Company Details
- Location
Karnal, Haryana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U85110HR1993PTC031972
- Company No.
031972
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Apr 1993
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
What products or services does J.R.S. Oryx Pharmaceuticals Pvt Ltd offer?
J.R.S. Oryx Pharmaceuticals Pvt Ltd offers a wide range of products and services, including Muscle Relaxant, Drotaverine Hydrochloride Mefenamic Acid Tablet, Pharmaceutical Medicine, Lycopene, Antifungal Injection, Tablet & Syrup, Itraconazole Capsule and Tablet, Hydroquinone Cream, Fertilizers and Soil Additives, Potassic Fertilizers, Antiparasitic Drug.
Who are the key members and board of directors at J.R.S. Oryx Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Surinder Pal  | Director | 26-Apr-1993 | Current |
| Rattan Sharma | Director | 16-Apr-1993 | Current |
Financial Performance of J.R.S. Oryx Pharmaceuticals.
J.R.S. Oryx Pharmaceuticals Pvt Ltd, for the financial year ended 2022, experienced significant reduction in revenue, with a 20.75% decrease. The company also saw a slight improvement in profitability, with a 3.22% increase in profit. The company's net worth Soared by an impressive increase of 68.97%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of J.R.S. Oryx Pharmaceuticals?
In 2021, J.R.S. Oryx Pharmaceuticals had a promoter holding of 88.95% and a public holding of 11.05%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Karnal Pharma Park Private LimitedRattan Sharma is a mutual person
- Cfc Pharma Cluster Private Limited
Rattan Sharma is a mutual person
Charges (Loans)
₹28.50 M
₹17.65 M
Charges Breakdown by Lending Institutions
- Others : 2.85 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 20 Apr 2018 | Others | ₹2.85 Cr | Open |
| 17 Sep 2020 | Others | ₹3.00 M | Satisfied |
| 09 Feb 2015 | L & T Finance Limited | ₹0.25 M | Satisfied |
| 18 Jun 2013 | Capital First Limited | ₹9.15 M | Satisfied |
| 26 May 2006 | Bank Of Punjab Limited | ₹2.50 M | Satisfied |
How Many Employees Work at J.R.S. Oryx Pharmaceuticals?
Unlock and access historical data on people associated with J.R.S. Oryx Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of J.R.S. Oryx Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped J.R.S. Oryx Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
